Table 3 Unadjusted and adjusted models for predictors of ≥90 day unstructured treatment interruption across 33 MSF sites providing ART care
Predictor | Level | Unadjusted hazard ratio (95 % CI) | p value | Adjusted hazard ratio (95 % CI) | p value |
|---|---|---|---|---|---|
Sex | Female | Ref. | Ref. | ||
Male | 0.94 (0.90–0.98) | <0.01 | 0.94 (0.90–0.98) | <0.01 | |
Age | <20 | Ref. | Ref. | ||
20–39 | 0.81 (0.74–0.89) | <0.01 | 0.87 (0.79–0.96) | <0.01 | |
40–59 | 0.79 (0.71–0.87) | <0.01 | 0.86 (0.78–0.96) | <0.01 | |
60+ | 0.86 (0.67–1.11) | 0.26 | 1.07 (0.82–1.39) | 0.61 | |
WHO stage at ART initiation | 1 | Ref. | Ref. | ||
2 | 1.07 (0.98–1.17) | 0.15 | 1.03 (0.95–1.13) | 0.47 | |
3 | 1.12 (1.05–1.21) | <0.01 | 1.10 (1.02–1.18) | <0.01 | |
4 | 1.23 (1.14–1.33) | <0.01 | 1.21 (1.12–1.30) | <0.01 | |
CD4 count at ART initiation* (cells/μL) | <200 | Ref. | Ref. | ||
200–350 | 0.87 (0.82–0.93) | <0.01 | 0.89 (0.83–0.95) | <0.01 | |
>350 | 0.86 (0.78–0.95) | <0.01 | 0.87 (0.78–0.96) | <0.01 | |
Marital status | Not married | Ref. | Ref. | ||
Married | 0.97 (0.93–1.01) | 0.18 | 1.02 (0.97–1.06) | 0.48 | |
Region | Africa | Ref. | Ref. | ||
Asia | 0.79 (0.75–0.83) | <0.01 | 0.82 (0.78–0.87) | <0.01 |